← All trials
NCT06994949
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 14, 2025
- Primary completion
- Jan 3, 2029
- Completion date
- Jan 3, 2029
- First posted
- May 29, 2025
- Last posted
- May 29, 2025
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonSponsor investigator
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of Texas at HoustonOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.